Your next
treatment is already
in trial.

Bisphosphonates have been the workhorse for two decades — but half of patients stop within a year. The monoclonal antibody trials we're running now are showing vertebral fracture reductions of 75% over 24 months. That's not incremental. That's a different conversation entirely.

Bone density screening still reaches fewer than 25% of eligible patients. Men are diagnosed years later than women — if at all. Our trials specifically include patients over 65 with vertebral compression, because that's where the treatment gap is most dangerous.

The concern I hear most often is side effects. When we compare denosumab biosimilar trials to standard bisphosphonate therapy, the discontinuation rates drop by more than half. Patients stay because the experience is different — subcutaneous injection every six months instead of daily pills.

Marrow's matching algorithm starts with four data points: your diagnosis date, current medication, T-score range, and ZIP code. From those, we can surface the three to seven trials with the highest likelihood of eligibility — before a single phone call. The average patient finds a match within 8 minutes.